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Patients with metastatic nasopharyngeal carcinoma have variable survival outcomes. We previously designed a scoring system to
better prognosticate these patients. Here, we report results on validation of this new prognostic index score in a separate cohort of
patients. Clinical features and laboratory parameters were examined in 172 patients with univariate and multivariate analyses and a
numerical score was derived for each independent prognostic variable. Significant independent prognostic variables and their scores
assigned included poor performance status (score 5), haemoglobin o12gdl
 1 (score 4) and disease-free interval (DFI) (DFIp6
months (score 10) or metastases at initial diagnosis (score 1)). Maximum score was 19 and patients stratified into three prognostic
groups: good, 0–3; intermediate, 4–8; poor, X9. When applied to a separate cohort of 120 patients, 59 patients were good, 43
intermediate and 18 poor prognosis, with median survivals of 19.6 (95% CI 16.1, 23.1), 14.3 (95% CI 12.3, 16.2) and 7.9 (95% CI 6.6,
9.2) months, respectively. (logrank test: P¼0.003). We have validated a new prognostic score with factors readily available in the
clinics. This simple score will prove useful as a method to prognosticate and stratify patients as well as to promote consistent
reporting among clinical trials.
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Nasopharyngeal carcinoma (NPC) occurs sporadically in the West
but constitute a major health problem in several parts of Asia,
including Southern China, Hong Kong and Singapore (Parkin,
2001). In Singapore, the incidence rate in Chinese is among the
highest in Asia and the disease ranks as the fifth most common
cancer among Chinese males (Chia et al, 2000). The histological
pattern of NPC among the Chinese population comprise mainly
the World Health Organization (WHO) types II (nonkeratinising)
and III (undifferentiated) (Chan et al, 1998). Both histological
types are often considered together as they share similar
epidemiological, clinical and serologic characteristics, as distinct
from the epidermoid carcinoma of the head and neck region seen
in the western population (Shanmugaratnam and Sobin, 1993;
Altun et al, 1995).
There is a high incidence of distant metastases with nonkera-
tinising or undifferentiated NPC, as compared to other epidermoid
carcinoma arising in the head and neck region (Reddy et al, 1995).
This is especially true for patients who present with locally
advanced disease (Ahmad and Stefani, 1986). A prospective study
showed a high rate of subclinical distant metastasis, with a
distinctive feature of bone marrow invasion (Micheau et al, 1987).
In addition, the incidence of distant failure after radiotherapy
treatment for locally advanced disease can be as high as 57% in N3
disease (Lee et al, 1992). In view of the high rate of systemic
relapse, chemotherapy has been incorporated into the primary
treatment of locally advanced disease in order to improve the
outcome. Concurrent chemoradiotherapy was shown to improve
overall and progression-free survival for locally advanced NPC in
the Intergroup study (Al-Sarraf et al, 1998) and this was replicated
in studies carried out in the endemic areas of Singapore (Wee et al,
2004), Hong Kong (Lee et al, 2004) and Taiwan (Lin et al, 2003).
However, a significant proportion of patients would still relapse
systemically despite combined modality therapy and many of these
patients would ultimately succumb to disseminated disease.
Patients with disseminated disease do not behave in a uniform
manner. It is hence not surprising to see significantly variable
results between studies of similar therapeutic manoeuvres in
patients with metastatic NPC. We have shown in our previous
study that by using several clinical and laboratory parameters, we
were able to define three prognostically distinct groups of patients
with disseminated NPC (Ong et al, 2003). We proposed that a
prognostic index scoring system using these parameters could be
used for a more accurate prognostic evaluation of a patient.
However more importantly, it can also be used for a more accurate
stratification of patients in prospective clinical studies and
hopefully help to standardise reporting results of any therapeutic
interventions.
We now report a follow-on study that reanalysed our previous
findings to define a new prognostic index score and to validate this
new score in a separate cohort of patients with disseminated NPC.
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sPATIENTS AND METHODS
Patients
All patients were treated at the Department of Medical Oncology,
National Cancer Centre between January 1994 and January 2003.
There were two different cohorts of patients: the first (Cohort 1)
was the group on which the new prognostic index score was
derived and included 220 patients treated between January 1994
and December 1999, while the second cohort (Cohort 2) was the
group on which the new score was validated. Cohort 2 included 99
patients treated between January 2002 and January 2003 and 21
patients (not included in our previous analysis for Cohort 1) from
a previous Institutional Review Board-approved phase II clinical
trial conducted in 1996 (Au et al, 1998).
All patients had a histological confirmation of NPC and had
computerised tomography (CT) scan of the posterior nasal space,
chest X-ray and/or CT scan of the thorax, ultrasound or CT scan of
the abdomen and bone radionuclide scan to identify the extent of
systemic disease. Patients were classified into the International
Union Against Cancer/American Joint Committee on Cancer
(UICC/AJCC) stages using the clinical and radiological data.
Pretreatment patient and disease characteristics, disease-free
interval (DFI) (time from the onset of primary radiotherapy or
chemoradiotherapy to the time of distant relapse), type of
chemotherapy given, best response to chemotherapy, type of
salvage chemotherapy given and date of death were recorded for
all patients.
Survival data
The primary end point of interest was metastatic survival.
Metastatic survival was defined as survival subsequent to the
development of distant relapse, that is, from the first diagnosis of
distant metastases to the time of death. Locoregional recurrence
was not considered a distant relapse. The survival status of all
patients was verified with Singapore’s national death registry for
Cohorts 1 and 2 as on 30 June 2000 and 31 December 2003,
respectively. The cohorts excluded patients who were nonresidents
of Singapore and as notification is mandatory in the event of death,
the mortality data obtained from the death registry was complete
and exhaustive.
Statistical analysis
The analysis to derive a new prognostic score was performed on
Cohort 1 and focused only on 172 patients who had received
chemotherapy. The original prognostic index score was based on
all patients including patients who were not treated with
chemotherapy (Ong et al, 2003). As chemotherapy has an impact
on survival outcome in patients with disseminated disease, there
was a need to rederive a new prognostic index score using only
patients from Cohort 1 who received palliative chemotherapy as all
the patients from Cohort 2 were treated with chemotherapy.
Univariate and multivariable analyses were performed using the
Cox proportion hazards model. The multivariable analyses were
undertaken with both forward and backward stepwise procedures
for identifying the independent prognostic variables. Factors that
were considered in the derivation of the new prognostic index
score included age, gender, performance status according to
Eastern Co-operative Oncology Group (ECOG) criteria, specific
metastatic sites, number of metastatic sites, metastasis at
presentation, stage at first diagnosis, DFI, leucocyte count,
haemoglobin (Hb) level, and albumin level, on the basis of our
previous analysis. In order to construct the new prognostic index
score, factors were entered as categorical values as far as possible
to keep the computations simple, although categorisation inevi-
tably will result in some loss of information. Pp0.05 was used as
the cutoff value of statistical significance for variable selection in
the multivariable modelling. The regression coefficient of each
independent prognostic variable (the b in the Cox regression
equation hazard ratio (HR)¼e
b) is then modified into an integer
numerical value to construct the new prognostic index score. The
patients were stratified, based on the new prognostic index score,
into three different risk groups with significantly different median
metastatic survivals.
The validation of the new prognostic index score was
subsequently performed on Cohort 2 patients. Overall and median
metastatic survival estimates and curves were obtained using the
Kaplan–Meier method and logrank test was used to compare
among the three prognostic groups stratified by the new score.
RESULTS
Patient and disease characteristics (Table 1)
Table 1 shows the characteristics of patients in both cohorts
who had received at least one line of palliative chemotherapy
at diagnosis of distant metastases. All patients had nonkeratinising
or undifferentiated NPC. There was a male predominance in
both cohorts. Most characteristics were similar between both
cohorts. The median age at diagnosis of metastases was 47 years
for Cohort 1 and 48 years for Cohort 2. In all, 35 (20.3%) patients
in Cohort 1 and 27 (22.5%) patients in Cohort 2 had metastases
at diagnosis. The majority had distant relapse after treatment
for locally advanced disease previously. Bone was the most
common site of metastasis, followed by liver, lung and distal
nodes. Most of the patients had multiple sites involved at diagnosis
of metastases.
The proportion of patients with good ECOG status of 0 and 1
was higher in Cohort 2 (95.8%) compared to Cohort 1 (87.8%)
(P¼0.07). Several chemotherapy regimens were used in the first-
line setting and these included Cisplatin and Fluorouracil,
Paclitaxel and Gemcitabine either alone or in combination with
Carboplatin.
Survival distribution
Patients from Cohort 2 appeared to have better survival, although
this was not statistically significant (logrank test P-value¼0.07).
See Figure 1. The median metastatic survival for patients in Cohort
1 was 12.9 months (95% CI 10.5,15.3) and that for patients in
Cohort 2 was 15.6 months (95% CI 13.2, 18.0). The 1-, 2- and 3-
year survival proportions were 52, 25 and 10% for Cohort 1 and 66,
33 and 15% for Cohort 2, respectively.
Univariate and multivariate analysis
The univariate analysis was performed on the 172 patients who
were treated with chemotherapy in Cohort 1. Factors considered in
the univariate analyses were based on our previous study and
included age, gender, performance status, laboratory parameters
such as Hb, leucocyte count and albumin level, stage at first
diagnosis, sites and number of metastases and DFI. The factors
associated with an adverse prognosis were anaemia
(Hbo12gdl
 1), ECOG X2, DFIp6 months, presence of multiple
metastases and liver metastases. See Table 2.
The variables included in the multivariate analysis were similar
to that used in the univariate analysis. Using a significance level of
0.05, the significant independent variables were Hb level
(Hbo12gdl
 1 with HR: 2.1), performance status (ECOGX2 with
HR: 2.6), DFI (metastasis at diagnosis and short DFI with HR: 1.2
and 7.7 respectively). See Table 3. These three variables predicted
negatively for metastatic survival.
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A numerical score was derived from the regression coefficient of
each of the three independent prognostic variables derived above,
namely, anaemia (Hbo12gdl
 1), ECOGX2 and DFI. A score of 0
was assigned if the factor was absent or 1, 4, 5 or 10 according to
the factor present. See Table 4. The new prognostic index score for
each individual patient was calculated by adding up the scores of
each independent factor. The maximum score obtainable was 19,
instead of 20 as metastasis at diagnosis and short DFI were
mutually exclusive. In view of the gaps between the scores, the
possible scores were 0–1, 4–6, 9–11, 14–16 and 19. The patients
were stratified into three prognostic groups based on the new
prognostic index score: 57 patients in the low-risk group (score:
0–3), 86 patients in intermediate-risk group (score: 4–8) and 25
patients in high-risk group (score: X9). The median metastatic
survivals for the three different risk groups were 25.3 (95% CI
17.7–33.9), 11.7 (95% CI 9.9–13.6) and 5.8 (95% CI 5.0–6.5)
months, respectively. (logrank test, Po0.0001). See Figure 2.
Validation of new prognostic index score
The new prognostic index score was applied to the patients in
Cohort 2. The proportion of patients in the low-risk, intermediate-
risk and high-risk groups were 49, 36 and 15%, respectively. The
median metastatic survivals of these three different groups were as
follows: 19.6 (95% CI 16.1–23.1), 14.3 (95% CI 12.3–16.2) and 7.9
(95% CI 6.6–9.2) months respectively (logrank, P¼0.003). See
Figure 3.
DISCUSSION
We previously presented our results on derivation of a prognostic
index score derived from all patients in Cohort 1 that included
those not treated with chemotherapy (Ong et al, 2003). However,
as Cohort 2 was used for validation of the score and all the patients
in Cohort 2 were treated, we elected to reanalyse Cohort 1 to
restrict the derivation of a new prognostic index score to only
patients given chemotherapy. The reason for the reanalysis is that
chemotherapy has an impact on survival outcome in patients with
disseminated NPC, although there are no randomised comparison
studies between chemotherapy and best supportive care (Fandi
et al, 1994; Hong et al, 1999). This is also supported by the fact that
incorporation of chemotherapy in locally advanced disease has
been shown to improve progression-free and overall survival
Table 1 Patient and disease characteristics
Cohort 1 Cohort 2
Characteristics
No. of
patients %
No. of
patients % P-value
No. of patients 172 120
Survival status See
logrank
test
Dead 130 75.6 91 75.8
Alive 42 24.4 29 24.2
Age, in years o0.001
Median 47 48
Interquartile range (40,54) (42,54)
Gender 0.32
Male 144 83.7 95 79.2
Female 28 16.3 25 20.8
ECOG status
a 0.07
0 18 10.5 19 15.8
1 133 77.3 96 80
2 14 8.1 2 1.7
3 6 3.5 3 2.5
4 1 0.6 0 0
Laboratory parameters
Albumin (gl
 1) 0.38
o40 128 74.4 90 75
X40 32 18.6 29 24.1
Hemoglobin (gl
 1) 0.003
o12 106 61.6 54 45
X12 63 36.6 66 55
UICC/AJCC stage at first diagnosis
b 0.002
I 5 2.9 2 1.7
IIA 1 0.6 4 3.3
IIB 31 18 4 3.3
III 39 22.7 39 32.5
IVA 20 11.6 16 13.3
IVB 27 15.7 16 13.3
IVC 33 19.2 27 22.5
Disease-free interval 0.16
Mets at diagnosis 35 20.3 27 22.5
p6 months 11 6.4 15 12.5
46 month 125 72.7 78 65
Sites of metastasis
Bone 118 68.6 79 65.8 0.26
Liver 74 43 63 52.5 0.12
Lung 65 37.8 51 42.5 0.41
Distant nodes 63 36.6 39 32.5 0.43
No. of metastatic sites 0.3
Single 69 40.1 41 34.2
Multiple 103 59.9 79 65.8
Prior chemotherapy before mets 0.58
Yes 14 8.1 12 10
No 158 91.9 108 90
Salvage chemotherapy 0.02
Yes 91 52.9 68 61.8
No 81 47.1 42 38.2
aECOG status refers to performance status as defined by the Eastern Cooperative
Oncology Group.
bUICC/AJCC refers to International Union against Cancer/
American Joint Committee on Cancer.
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Figure 1 Survival curves for Cohorts 1 and 2. There is no statistically
significant difference in metastatic survival between the two cohorts.
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s(Al-Sarraf et al, 1998; Lin et al, 2003; Wee et al, 2004). Thus, with
reanalysis, we have eliminated the bias with the use of
chemotherapy and make the two cohorts more comparable.
We found that DFI, Hb level (o12gdl
 1) and poor performance
status (ECOGX2) were significant negative prognostic factors in
patients treated with chemotherapy and these three independent
variables were used in the derivation of the new prognostic index
score. Metastasis at diagnosis and short DFI were regarded as two
separate categories within the same DFI variable and thus were
mutually exclusive. The natural history of a disease is dependent
on the interaction of both patient and disease factors. Anaemia can
be related to the disease process itself, host-related factors or
treatment given and has been shown to be associated with
significant reduction in survival in various cancers, other than
NPC (Caro et al, 2001; Bokemeyer et al, 2002). Anaemia may reflect
not only a biologically more aggressive tumour but may be a
mediating factor to resistance to treatment and this has been
demonstrated in retrospective studies on cervical cancer treated
with chemoradiation (Obermair et al, 2001). The negative
prognostic factor of a poor performance status has been shown
in many other tumour types as well (Paesmans et al, 1995; Polee
Table 2 Univariate analysis of patients treated with chemotherapy in
Cohort 1 (N¼172)
Factor
No. of
patients
No.
alive
Hazard ratio
(95% CI) P-value
Gender
Female 28 6 Baseline
Male 144 36 0.66 (0.41–1.04) 0.075
Age, in years
p54 78 23 Baseline
46–65 84 16 1.31 (0.92–1.88) 0.14
465 10 3 1.79 (0.81–3.96) 0.15
Albumin, gl
 1
X04 32 10 Baseline
o40 128 31 1.43 (0.89–1.88) 0.13
Haemoglobin, gdl
 1
X12 63 28 Baseline
o12 106 14 2.61 (1.76–3.87) o0.001
ECOG status
a
0–1 151 41 Baseline
2 14 1 2.24 (1.26–4.00) 0.006
3–4 7 0 4.19 (1.93–9.18) o0.001
Leucocyte count,  10
9 l
 1
o4 26 4 Baseline
4–11 112 35 0.77 (0.48–1.24) 0.29
411 31 3 1.46 (0.83–2.56) 0.19
UICC/AJCC stage at first
diagnosis
b
I–II 37 8 Baseline
III–IVB 86 23 1.21 (0.78–1.89) 0.38
IVC 33 9 1.41 (0.81–2.45) 0.22
Bone metastasis
No 42 10 Baseline
Yes 118 27 1.24 (0.82–1.85) 0.3
Liver metastasis
No 97 26 Baseline
Yes 74 16 1.60 (1.13–2.28) 0.008
Lung metastasis
No 106 27 Baseline
Yes 65 15 1.19 (0.83–1.70) 0.35
Distal node metastasis
No 107 19 Baseline
Yes 63 22 0.81 (0.56–1.18) 0.27
Number of metastatic sites
Single 69 17 Baseline
Multiple 103 25 1.55 (1.08–2.21) 0.017
Disease-free interval
46 months 125 32 Baseline
p6 months 11 1 4.03 (2.02–8.02) o0.001
Metastases at diagnosis 35 9 1.25 (0.81–1.94) 0.31
aECOG status refers to performance status as defined by the Eastern Cooperative
Oncology Group.
bUICC/AJCC refers to International Union against Cancer/
American Joint Committee on Cancer.
Table 3 Significant independent variables from multivariate analysis for
patients treated with chemotherapy in Cohort 1 (N¼172)
Factor Hazard ratio (95% CI) P-value
Haemoglobin level (o12gdl
 1) 2.067 (1.34–3.17) 0.001
Performance status (ECOG X2
a) 2.585 (1.45–4.59) 0.001
Disease-free interval
Metastasis at diagnosis 1.21 (0.75–1.95) 0.031
p6 months 7.656 (2.23–26.25)
aECOG refers to performance status as defined by the Eastern Cooperative
Oncology Group.
Table 4 New prognostic index score and risk groups
Factor Score b (hazard ratio¼e
b)
a
Haemoglobin level (o12gdl
 1) 4 0.73
Performance status (ECOG X2
b) 5 0.95
Disease-free interval
Metastasis at diagnosis 1 0.19
p6 months 10 2.04
Maximum score 19
Low risk: score 0–3; intermediate risk: score 4–8; high risk: score X9.
ab¼Regression Coefficient.
bECOG refers to performance status as defined by
the Eastern Cooperative Oncology Group.
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Figure 2 Survival by new prognostic index grouping derived from
patients in Cohort 1. There is a clear demarcation of survival differences
between the three risk groups.
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set al, 2003; Motzer et al, 2004). Patients with poor performance
status do not tolerate treatment well and it may also be a reflection
of the more advanced state of the cancer.
Patients who present with metastasis at diagnosis can be a result
of delay in seeking medical attention or more likely, a reflection of
the aggressive nature of the disease such that it is widespread by
the time the patient becomes symptomatic. Having a short DFI is
also reflective of an aggressive disease and has been convincingly
shown to portend a poorer outcome in other tumours such as
ovarian cancer (Markman et al, 1991). Our analysis showed that a
short DFI after initial radiotherapy or chemoradiotherapy for the
primary tumour had a worse prognostic score compared to
metastasis at diagnosis and this is likely due to emerging
chemoresistant clones within the tumour of those patients who
relapse shortly after treatment.
A study by Teo et al (1996) showed that short DFI, the presence
of liver metastasis and age at diagnosis were prognostic for
metastatic survival in metastatic NPC. Short DFI is included as a
factor in our new prognostic index score but the other two
variables were found to be not statistically significant on multi-
variate analysis. This may be a result of our population of patients
being limited to only those treated with chemotherapy and the
treatment likely negated the prognostic significance of age and site
of metastasis. Statistical issues, such as variations in modelling
procedure in small to moderate size data sets between the different
studies, could be an alternative explanation.
The metastatic survival of patients with disseminated NPC
treated with chemotherapy is highly variable and our findings
provide further supportive evidence for that. In Cohort 1, at the
time of analysis in June 2000, the metastatic survival varied from 1
to 72 months. Similarly, for Cohort 2, the metastatic survival
duration varied from 1 month to 103 months: 10 patients died
within 3 months of diagnosis of metastatic disease despite
chemotherapy, while 13 patients are still alive after 2 years. In
fact, one patient survived 8 years 7 months while another three
lived beyond 4 years after diagnosis of metastatic disease. A
number of studies have reported similar findings, with several
long-term survivors with the use of chemotherapy in metastatic
NPC (Chan et al, 1997; Fandi et al, 2000). Based on the results of
our studies, it is possible for single-arm studies or randomised
studies that are inadequately powered or stratified to report
spuriously improved survival outcome with a new therapeutic
intervention because of biased patient selection alone. As a result
of this heterogeneity, it is imperative that a method be developed
to better prognosticate and stratify patients for more accurate
assessment of efficacy of any new therapeutic interventions.
It is important to note that the new prognostic index score
resulted in clear demarcation of three prognostically different
groups with nonoverlapping confidence intervals of the median
survival durations and this demarcation was replicated in the
separate cohort of patients. Another important point to note is that
the new prognostic index score incorporates clinical data that are
used in routine patient care in most institutions.
There is accumulating evidence for the use of biomarkers in the
detection and prognostication of NPC. The biomarkers include
circulating markers in the blood, such as Epstein–Barr virus
(EBV) DNA (Chien et al, 2001) and CYFRA 21-1 (Ma et al, 2004),
as well as tumour immunohistochemical markers such as the
expression of multidrug-resistance protein (Hsu et al, 2002),
epidermal growth factor receptors (Chua et al, 2004) and signal
transducers and activators of transcription factors (Hsiao et al,
2003). Among them, plasma EBV DNA has been the most validated
and has been shown to be a predictor of poor survival after
radiotherapy for local disease (Chan et al, 2002). However, these
biomarkers are not readily available in most institutions and they
are yet to be validated as prognostic factors in the metastatic
setting.
It is conceivable that similar prognostic classifications can be
designed and used for other disseminated solid tumours as well,
for instance breast or colorectal cancers. Such a prognostic
classification based on combination of patient and laboratory
factors may be able to categorise patients with disseminated
disease more accurately as shown in NPC in this study and hence
will be useful for stratifying patients in randomised studies.
We have validated a new prognostic index score in metastatic
NPC patients treated with chemotherapy. This new prognostic
index score can stratify patients into three different prognostic
groups with significantly different median metastatic survivals.
This prognostic classification system will be useful for more
accurate prognostication of patients with disseminated NPC. In
addition, it can prove useful in the design of clinical trials for
metastatic NPC as it can more accurately stratify patients into
groups with fairly consistent outcome and thus make the results
more comparable and interpretable.
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